Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 17/07/2024 BST 5-day change 1st Jan Change
4.29 USD -6.13% Intraday chart for Zentalis Pharmaceuticals, Inc. +8.88% -71.68%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell Small Cap Comp Value Index CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell 3000 Value Index CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell 2500 Value Index CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell 3000 Growth Index CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell 2000 Value Index CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell 3000E Growth Index CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell 2000 Growth Index CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell 2500 Growth Index CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell Small Cap Comp Growth Index CI
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell 3000E Value Index CI
UBS Downgrades Zentalis Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $5 From $28 MT
US Equity Markets Close Up Tuesday Following Less-Than-Expected Retail Sales Growth MT
Sector Update: Health Care Stocks Edge Up Late Afternoon MT
Sector Update: Health Care MT
Jefferies Downgrades Zentalis Pharmaceuticals to Hold From Buy, Cuts Price Target to $6 From $42; Shares Plummet MT
Top Midday Decliners MT
Morgan Stanley Downgrades Zentalis Pharmaceuticals to Equalweight From Overweight, Cuts PT to $8 From $38; Shares Plunge MT
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $10 From $32, Maintains Buy Rating MT
Wedbush Downgrades Zentalis Pharmaceuticals to Underperform From Neutral, Cuts Price Target to $4 From $15 MT
Wells Fargo Downgrades Zentalis Pharmaceuticals to Equal Weight From Overweight, Lowers Price Target to $9 From $29 MT
Zentalis Pharmaceuticals Shares Fall After FDA Places Partial Clinical Hold on Three Studies MT
Traders Digest Retail Sales Data Ahead of Holiday Break, Driving Muted Premarket Action for US Equity Futures MT
Zentalis Pharmaceuticals Shares Slide on Partial Clinical Holds on Cancer Drug Studies DJ
Transcript : Zentalis Pharmaceuticals, Inc. - Special Call
US FDA puts partial clinical hold on Zentalis' cancer drug studies; shares drop RE
Chart Zentalis Pharmaceuticals, Inc.
More charts
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
4.57 USD
Average target price
10.7 USD
Spread / Average Target
+134.14%
Consensus
  1. Stock Market
  2. Equities
  3. ZNTL Stock
  4. News Zentalis Pharmaceuticals, Inc.
  5. Sector Update: Health Care Stocks Edge Up Late Afternoon